Skip to main content
. 2020 Nov 18;3(1):vdaa158. doi: 10.1093/noajnl/vdaa158

Table 1.

Baseline Characteristics of 867 Glioblastoma Patients Included in the Final Analysis

Parameter N (%) or Mean (±SD)
Age, years 63.83 (±11.51)
Sex, male 501 (57.8%)
Medical history
 Arterial hypertension 450 (51.9%)
 Diabetes mellitus 150 (17.3%)
 Hypothyroidism 104 (12.0%)
 History of cancer 127 (14.6%)
KPS at admissiona
 Good (90–100%) 338 (39.7%)
 Reduced (70–80%) 414 (48.6%)
 Poor (≤60%) 100 (11.7%)
EOR, biopsy 247 (28.5%)
Tumor location
 Frontal lobe 305 (35.2%)
 Temporal lobe 239 (27.6%)
 Parietal lobe 103 (11.9%)
 Occipital lobe 129 (14.9%)
 Midline/Infratentorial/Bi-hemispheric 91 (10.5%)
Molecular status
 MGMT methylation 310 (41.6%b)
 IDH1 mutation 17 (3.1%c)

EOR, extent of resection; IDH1-Isocitrate dehydrogenase 1 mutation; MGMT, O[6]-methylguanine-DNA methyltransferase promoter methylation; N, number of cases; SD, standard deviation.

a15 cases (1.7%) with missing KPS score.

b121 cases (14%) with missing MGMT promoter methylation status.

c311 cases (35.9%) with missing IDH1 mutation status.